Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...136137138139140141142143144145146...401402»
  • ||||||||||  Journal:  Interventions to improve nutritional status for older patients with cancer - a holistic approach is needed. (Pubmed Central) -  Jan 26, 2023   
    Multimodal interventions including nutrition have the potential to improve patient-centred outcomes in older adults with cancer during the continuum of care, from prehabilitation to palliative care. Early, integrated supportive care applying the right intervention in the right setting at the proper time along with personalized antitumor treatment is the cornerstone of optimal holistic cancer care.
  • ||||||||||  LONG-TERM OUTCOMES IN SEPTIC CRITICALLY ILL PATIENTS WITH PREEXISTING SARCOPENIA () -  Jan 25, 2023 - Abstract #SCCM2023SCCM_2125;    
    While sarcopenia has been associated with increased 1-year mortality following abdominal sepsis, our study did not distinguish between different sources of sepsis, and it did not replicate these prior results. Further studies are needed to validate our findings in a larger patient sample.
  • ||||||||||  Journal:  Associations between oral health status and risk of fractures in elder adults. (Pubmed Central) -  Jan 25, 2023   
    Results from multivariate linear regression analysis demonstrated significant relationships between total tooth number and probabilities of fracture in male and female elderly. The interdisciplinary approach for handling osteoporosis and sarcopenia including dentists, physicians is necessary to facilitate a better quality of life in the elderly.
  • ||||||||||  Review, Journal:  Acute sarcopenia. (Pubmed Central) -  Jan 24, 2023   
    Prevention and management of acute sarcopenia rely on exercise during admission, but the quality of evidence is still low. Nutrition intervention and drugs may have a role, but more research is needed.
  • ||||||||||  Enrollment status, Trial completion date, Trial initiation date, Trial primary completion date:  The Change in Temporal Muscle Thickness in Stroke Patients (clinicaltrials.gov) -  Jan 23, 2023   
    P=N/A,  N=150, Enrolling by invitation, 
    Based on WGCNA, our study identified apoptosis pathway and LRRK2 that acted as essential components in the etiology of sarcopenia and neuroticism, which may enhance our fundamental knowledge of the molecular mechanisms underlying the disease. Recruiting --> Enrolling by invitation | Trial completion date: Sep 2022 --> Apr 2023 | Initiation date: Apr 2022 --> Jul 2022 | Trial primary completion date: Sep 2022 --> Mar 2023
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date:  A Novel/Common Approach for Temporalis Muscle Thickness Measurement (clinicaltrials.gov) -  Jan 23, 2023   
    P=N/A,  N=60, Enrolling by invitation, 
    Recruiting --> Enrolling by invitation | Trial completion date: Sep 2022 --> Apr 2023 | Initiation date: Apr 2022 --> Jul 2022 | Trial primary completion date: Sep 2022 --> Mar 2023 Not yet recruiting --> Enrolling by invitation | Trial completion date: Aug 2022 --> Feb 2023 | Trial primary completion date: Aug 2022 --> Nov 2022
  • ||||||||||  Review, Journal:  Age-Related Dysfunction in Proteostasis and Cellular Quality Control in the Development of Sarcopenia. (Pubmed Central) -  Jan 22, 2023   
    This information is important for developing effective therapeutic strategies that mitigate or prevent sarcopenia and associated disability. This review identifies recent and historical understanding of the molecular mechanisms of proteostasis driving age-associated muscle loss and suggests potential therapeutic interventions to slow or prevent sarcopenia.
  • ||||||||||  metformin / Generic mfg., losartan / Generic mfg.
    Review, Journal:  Insights into Pathogenesis, Nutritional and Drug Approach in Sarcopenia: A Systematic Review. (Pubmed Central) -  Jan 22, 2023   
    Creatine, leucine, branched-chain amino acids, omega 3, and vitamin D can show benefits. Although with controversial results, medications such as Metformin, GLP-1, losartan, statin, growth hormone, and dipeptidyl peptidase 4 inhibitors have also been considered and can alter the sarcopenic's metabolic parameters, protect against cardiovascular diseases and outcomes, while protecting muscles.
  • ||||||||||  Journal:  From Sarcopenia to Depressive Symptoms in Elderly: A Path Analysis. (Pubmed Central) -  Jan 22, 2023   
    The presented path model may assist rehabilitation centers in developing strategies to screen for sarcopenia and risk of malnutrition, and promote physical activity in elderly, aiming to prevent their negative effects on mental health. For the elderly currently affected by sarcopenia, we consider regenerative medicine and stem cell therapy, which, in view of their etiology, could be a potential therapeutic strategy for sarcopenia.
  • ||||||||||  Journal:  Effect of Familial Longevity on Frailty and Sarcopenia: A Case-Control Study. (Pubmed Central) -  Jan 22, 2023   
    Familial longevity was also associated with less obesity, insomnia, pain, and polypharmacy and a higher education level and total and low-density lipoprotein cholesterol. The results suggest an inherited genetic component in the frailty phenotype, while the sarcopenia association with familial longevity remains challenging.
  • ||||||||||  Review, Journal, Immunomodulating:  Nano-Immunomodulation: A New Strategy for Skeletal Muscle Diseases and Aging? (Pubmed Central) -  Jan 22, 2023   
    Here we exhaustively review the state-of-the-art regarding the use of nano-sized materials to modulate the aberrant immune response that characterizes some physio-pathological muscle conditions, such as MDs or sarcopenia (the age-dependent loss of muscle mass). Based on our learnings from cancer and immune tolerance induction, we also discuss further opportunities, challenges, and limitations of the emerging field of nano-immunomodulation.
  • ||||||||||  Review, Journal:  Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges. (Pubmed Central) -  Jan 22, 2023   
    In this review, we discuss the potential for oligonucleotide therapies to combat the unmet clinical need in musculoskeletal disorders by evaluating the successes of oligonucleotides to modify candidate pathological gene targets and cellular processes in relevant tissues and cells of the musculoskeletal system. Further, we discuss the challenges that remain for the clinical development of oligonucleotides therapies for musculoskeletal disorders and evaluate some of the current approaches to overcome these.
  • ||||||||||  Journal:  Evaluation of Frailty Measures and Short-Term Outcomes after Lung Transplantation. (Pubmed Central) -  Jan 22, 2023   
    Both phenotypic and cumulative deficit models measured pre-transplant associate with short-term outcomes after lung transplant. Cumulative deficit measures of frailty may be more relevant in the first 90 days post-transplant, whereas phenotypic frailty may have a stronger association with one-year survival.
  • ||||||||||  Journal:  Clinical nutrition: what's new in 2022 (Pubmed Central) -  Jan 21, 2023   
    This review will highlight the key messages of three guidelines focusing on nutritional management in the geriatric population, micronutrient disorders, and sarcopenic obesity. Special emphasis will be directed towards recommendations impacting ambulatory clinical practice.
  • ||||||||||  Journal:  Limited physician knowledge of sarcopenia: A survey. (Pubmed Central) -  Jan 21, 2023   
    Sarcopenia, a condition that can have a major impact on older adults as they age, has not been fully incorporated into the knowledge base and practices of active physicians. The survey data suggest that improving physician familiarity with sarcopenia and having universal agreement on criteria for diagnosis may increase the screening for and treatment of sarcopenia.
  • ||||||||||  Review, Journal:  A scoping review on nutritional intake and nutritional status in people with a major dysvascular lower limb amputation. (Pubmed Central) -  Jan 20, 2023   
    However, these results should be interpreted with caution, because of the limited quality of the studies available. Studies high in methodological quality and high in hierarchy of evidence are needed.IMPLICATIONS FOR REHABILITATIONThe proportion of people with a poor nutritional status in the major dysvascular lower limb amputation population is inconclusive.Poor nutritional status seems to affect clinical outcomes negatively.More uniformity in assessment of malnutrition in the major dysvascular lower limb amputation population is needed.